Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
positive symbols : Amyt save search
COMP Adopts Positive Opinion on Orphan Designation for Mycapssa® for the Treatment of Carcinoid Syndrome Associated with Neuroendocrine Tumors
Published: 2022-12-19 (Crawled : 15:00) - biospace.com/
AMYT | $14.7 0.0% 2.4M
|
Health Technology
|
| O: -1.08%
H: 2.9%
C: 1.59%
mycapssa treatment designation tumors positive
COMP adopts positive opinion on Orphan Disease Designation for Mycapssa® for the treatment of Acromegaly
Published: 2022-10-18 (Crawled : 14:00) - biospace.com/
AMYT | $14.7 0.0% 2.4M
|
Health Technology
|
| O: 0.24%
H: 0.0%
C: 0.0%
mycapssa treatment designation disease positive
CHMP adopts positive opinion for Mycapssa® for the treatment of Acromegaly
Published: 2022-09-16 (Crawled : 12:00) - globenewswire.com
AMYT | $14.7 0.0% 2.4M
|
Health Technology
|
| O: -0.41%
H: 4.76%
C: 4.08%
mycapssa treatment chmp positive
CHMP adopts positive opinion for Filsuvez® for the treatment of Dystrophic and Junctional EB
Published: 2022-04-22 (Crawled : 14:20) - globenewswire.com
AMYT | $14.7 0.0% 2.4M
|
Health Technology
|
| O: 0.26%
H: 14.69%
C: 14.3%
filsuvez treatment chmp positive
Amryt Announces Positive Long-Term Safety and Efficacy Data for Mycapssa® (oral octreotide) from the 2nd Year of OPTIMAL Open Label Extension Study in Acromegaly Patients
Published: 2022-04-13 (Crawled : 17:00) - biospace.com/
AMYT | $14.7 0.0% 2.4M
|
Health Technology
|
| O: 1.45%
H: 3.5%
C: 0.65%
mycapssa label positive
Amryt Announces Positive Interim Analysis Data From Open Label Phase of EASE Phase 3 Trial in EB
Published: 2022-03-26 (Crawled : 16:20) - globenewswire.com
AMYT | $14.7 0.0% 2.4M
|
Health Technology
| Email alert
Add to watchlist
trial label positive phase 3
Amryt Announces Positive Long-Term Safety and Efficacy Data confirming the role for Mycapssa® (oral octreotide) in the management of Acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide
Published: 2022-01-11 (Crawled : 15:00) - biospace.com/
AMYT | $14.7 0.0% 2.4M
|
Health Technology
|
| O: 1.59%
H: 0.0%
C: 0.0%
The Lancet Diabetes & Endocrinology Publishes Positive Results for the MPOWERED Phase 3 Trial for Mycapssa® (oral octreotide) in Acromegaly Patients
Published: 2022-01-04 (Crawled : 12:30) - globenewswire.com
AMYT | $14.7 0.0% 2.4M
|
Health Technology
|
| O: -1.3%
H: 0.0%
C: 0.0%
mycapssa trial diabetes positive results positive results phase 3 lancet
Amryt Receives Positive Feedback from the FDA on the Path Forward for Myalept® (metreleptin) Indication in Partial Lipodystrophy
Published: 2021-03-23 (Crawled : 08:00) - globenewswire.com
AMYT | $14.7 0.0% 2.4M
|
Health Technology
|
| O: -2.82%
H: 5.45%
C: 0.98%
lipodystrophy fda positive
Gainers vs Losers
| 71% | 29% |
Top 10 Gainers
AGBA | News | $1.27 217.5% 120M
|
Finance
EGOX | $0.0503 39.72% 320M
|
RWOD | $10.52 31.56% 5.9M
|
n/a
ZCMD | $1.905 31.38% 30M
|
Commercial Services
MRDB 4 | $0.536 27.65% 2M
|
n/a
BSFC | $0.0822 27.64% 75M
|
Manufacturing
TPET | $0.4121 25.68% 45M
|
n/a
NVFY | $2.65 25.59% 33M
|
Consumer Durables
INDO | $5.1 25.0% 15M
|
Energy Minerals
CHRO | $1.53 24.9% 100K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.